CA-QUECTEL-WIRELESS
3.1.2023 10:01:41 CET | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, has announced the launch of the latest addition to its LTE module portfolio, the industrial grade EG800Q-EU LTE Cat.1 bis wireless communication module. An ultra-compact module in LGA form factor, the EG800Q-EU offers greater flexibility in IoT designs and enables a wider range of IoT use cases, particularly for size sensitive applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230103005121/en/
EG800Q-EU - ultra-compact, high-performance Cat.1 bis solution (Graphic: Business Wire)
Based upon the Qualcomm® QCX216 LTE IoT Modem from Qualcomm Technologies Inc., the EG800Q-EU is an LTE only module for customers in Europe, the Middle East, Africa, Australia, New Zealand, and Israel markets with LTE FDD band coverage of B1/ 3/ 5/ 7/ 8/ 20/ 28. The module delivers a maximum downlink data rate of 10 Mbps while enhancing battery life, critical for a variety of high-performing IoT applications including smart utility meters, asset trackers, e-mobility, parking meters, and home automation.
The EG800Q-EU’s support of Cat.1 bis allows it to use a single antenna, balancing cost and performance and making the module an ideal solution for IoT terminals that are designed to be compact and cost-effective.
“We feel very excited that our EG800Q-EU is one of the industry’s first Cat.1 modules based on the Qualcomm QCX216 LTE IoT Modem, a cost-optimized, power efficient global Cat.1 bis modem,” said Norbert Muhrer, President and CSO of Quectel. “The module’s unrivalled advantages make it ideal for a multitude of mid-range use cases and deployment scenarios which demand reliable and cost-effective communication solutions.”
The EG800Q-EU has a compact form factor of 15.8mm × 17.7mm × 2.4mm, enabling integrators and developers to design size sensitive applications easily. Its advanced LGA package enables fully automated manufacturing for high-volume applications.
The EG800Q-EU also provides a rich set of Internet protocols, and industry-standard interfaces including USB 2.0/ UART/ I2C/ PCM/ USIM, extending the suitability of the module to a variety of IoT applications such as asset management, remotely managed access control (RMAC), and smart grid. Additionally, the module supports DFOTA to enable automatic firmware upgrade and integrated Wi-Fi positioning services when there is no GPS signal indoors.
To help customers to facilitate their designs, Quectel offers a variety of high-performance LTE Cat.1 antennas which boost wireless connectivity significantly. IoT developers can bundle the EG800Q-EU module with Quectel’s antennas and pre-certification services, reducing both cost and time-to-market for their Cat.1 devices.
Engineering samples of the Quectel EG800Q-EU are available now.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas and IoT connectivity.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patented technologies are licensed by Qualcomm Incorporated.
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005121/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom